Table 2 Dose intensity, Grade 3/4 adverse events and objective tumor responses.
ID Number | Number of Completed Cycles | Total Cumulative Dose (mg) | Grade 3/4 Adverse Events | Objective Response |
|---|---|---|---|---|
0001–1103 | 2 | 46.8 | None | PD |
0002–2101 | 1 | 23.7 | None | PD |
0002–2102 | 2 | 17.0 | ALP NOS increased Amylase increased Lipase increased Liver function tests NOS increased | PD |
0003–3101 | 2 | 54.0 | None | PD |
0003–3102 | 2 | 45.1 | Ureteric obstruction | PD |
0004–4101 | 4 | 115.2 | Pyrexia Rigors Hyponatremia Hypoxia | SD × 4 mo. |
0004–4102 | 2 | 42.7 | Pyrexia Rigors | PD |
0004–4103 | 2 | 43.6 | ALT increased Hypokalemia Rash NOS | PD |
0004–4104 | 4 | 85.4 | Arthralgia Rigors | SD × 4 mo. |